Company Overview and News
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
Seasoned dividend investors know that there are big differences between stocks that pay dividends and companies that legitimately have “dividend stocks.” Companies in the latter category have, in many cases, displayed lengthy commitments to not only paying dividends but growing payouts as well.
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
Procter & Gamble Co. (NYSE: PG) posted a slim share price gain of 0.1% last week, not enough to shake off the company’s ranking as the worst performing Dow Jones industrial stock of this year. So far in 2018, the shares have lost 20.1%. This is P&G’s fifth consecutive week as the Dow’s worst stock for the year.
It was nearly three years ago this week that it last began. The U.S. stock market was moving in full stride in 2015 as we progressed through another calendar year. But then the market closed on May 21. And over the next nine months, investors increasingly found themselves standing on the brink of the next stock bear market. Despite turning out to be a “false” alarm, it is our most recent and relevant example of what we might reasonably expect if today’s ongoing struggles since the late January highs begin to manifest into something deeper.
Roth IRAs are going to be the most fun to write about of any of the postings in this series. There are just so many benefits to Roth accounts that they are fun to think about. It isn't just about taxes, but they're good place to start.
Since nobody can seem to agree on what is an asset bubble, it's that much more difficult to try and estimate its end. A bubble stops being a bubble only when the people participating decide to question the rationalizations they've invented to keep them complacently inside of it. It's most often just that vague sense the world isn't turning out the way everyone was just the day before so sure it would.
Micron, due to its high implied volatility and strong techncials, is a good covered call candidate at present.
I’ve been relatively skeptical toward Alphabet Inc (NASDAQ:GOOGL, NASDAQ:GOOG) stock for some time now, and as such have missed out on the big run in GOOG stock. While Alphabet stock has been mostly range-bound since late October, it has made some progress. At the least, $1,000 looks like support for GOOG, instead of the resistance that level offered last year.
I have been banging the drum about a market correction, but I suppose I just might croak waiting for one. The bottom line is that I have been wrong or early. Being early is still being wrong, folks, and I won't hide from the facts.
This article is part of a series that provides an ongoing analysis of the changes made to Berkshire Hathaway’s (NYSE:BRK.A) (NYSE:BRK.B) 13F stock portfolio on a quarterly basis. It is based on Warren Buffett’s regulatory 13F Form filed on 05/15/2018. Please visit our Tracking 10 Years Of Berkshire Hathaway's Investment Portfolio article series for an idea on how his holdings have progressed over the years and our previous update for the moves in Q4 2017.
The first quarter of 2018 has been solid regarding profits. They grew by almost 26% — the best Q1 return in eight years. Unfortunately, investors aren’t buying any of the good news, and that’s especially true of consumer stocks, which are getting hammered year to date.
Within the broader equity market these days, there probably isn't a sector that is more out of favor than Consumer Staples. As consumers have shifted their tastes away from brands that dominated the economy of their parents' generation, the stocks in the sector have been big market laggards. The chart below shows the relative strength of the Consumer Staples sector versus the S&P 500 since 1980. A rising line indicates outperformance on the part of the Consumer Staples sector, while a falling line indicates underperformance.
Here we go, here we go! It is finally May and you know what that means… PLAYOFF BASKETBALL! But that's not what I'm excited about today. One of my favorite parts about turning the calendar is taking a few moments to see how I performed in the previous month. After all, we are all obsessed with numbers and love charting our progress. So naturally I LOVE putting together my April dividend income summary.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET